arm in Biological Technology

Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial

TSX Exchange Symbol: RVX CALGARY, Oct. 21 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that the ongoing double blind placebo controlled Phase 1b/2a study in subjects with normal and low HDL is progressing as planned. The subjects in the first group rec...

Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study

Summary: Genmab has Amended the Design of the Ofatumumab Pivotal Study in Rituximab Refractory Follicular Non-Hodgkin's lymphoma and Reduced the Number of Patients to Approximately 81 COPENHAGEN, September 27 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it ...

Amicus Therapeutics Announces Second Quarter 2009 Financial Results

...zyme replacement therapy (ERT) or who have not received ERT for at least six months prior to the start of treatment with Amigal. The Amigal treatment arm dose and regimen will be 150 mg every other day. The primary endpoint will be the change in the amount of kidney interstitial capillary GL-3 ...

SK Life Sciences has Licensed Pristima

... Dr. Hong Wook Kim, Director, Non-clinical Development of SK Life Science, Inc., remarked that "SKLSI is building its research and development arm and required the most modern toolset in order to address current and future projects." About SK Life Sciences - SK Life Science, Inc. ( http:...

Neurocrine Biosciences Reports Second Quarter 2009 Results

...d. The first three months of the study included three arms; elagolix 150 mg, elagolix 250 mg, and placebo. After the initial three months, the placebo arm was re-randomized into one of the two elagolix arms. These 24 Week results of the Lilac Petal Study again confirmed that elagolix has clinically meani...

PROLOR Biotech Acquires License Option from Yeda for Development of Long-Acting Anti-Obesity Drug

..., today announced that it has entered into an evaluation and option agreement with Yeda Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science . Under the terms of the evaluation and option agreement, PROLOR may obtain from Yeda a license to develop a ...

Looking Older Than You Are May Have Little to Do With Wrinkles

...smetic purposes for 10 years. Both experts are often linked in research, training and video training modules for Dermik. Dermik is the dermatology arm of Sanofi Aventis, one of Europe's largest pharmaceutical companies. Full cosmetic application approval from the FDA is expected in the U.S within mon...

Monitoring water through a snake's eyes

...susceptible. "It's unlikely that someone will poison the water supply in Afghanistan," says Prof. Katzir, "but America is in grave danger and needs to arm itself against chemical threats to its drinking water. "With our naked eyes we can't distinguish between pure water and water that contains a small...

Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa

...ined in the 150 mcg corifollitropin alfa treatment arm (38.9 percent per started cycle) was similar to th...rate in the 150 mcg corifollitropin alfa treatment arm (38.9 percent per started cycle) was similar to t... 3.4 percent in the corifollitropin alfa treatment arm versus 1.6 percent in the rFSH treatment group.(5)...

Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors

...as the Company grows and continues to move products through the development pipeline." Russell Greig is President of SR One, the venture capital arm of GlaxoSmithKline (GSK). Prior to joining SR One, he served as President of GSK's Pharmaceuticals International from 2003 to 2008, and also served o...

2009 Medical Innovation Summit at Cleveland Clinic to Highlight the Latest Developments in Cancer Care

... and Premium Sponsor, General Electric. About Cleveland Clinic Innovations CC Innovations , the commercialization and innovation arm of Cleveland Clinic, organizes the Medical Innovation Summit, promotes innovation and is responsible for commercialization of all Cleveland Clinic tec...

YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB

...rmaceutical Co. in Korea recently collaborated on a Phase I trial treating patients with palliative radiotherapy for NSCLC. The data from the Canadian arm of the trial were presented at ASCO 2008 and indicated that the combination of nimotuzumab with radiation was feasible and safe and has the potential ...

Campbell Alliance Adds Industry Veterans Jon W. McGarity and David Lilley as Executive Vice Presidents

... global contract research organization (CRO); and NovaQuest, the investment arm of Quintiles. "In this market environment, executive management teams...rmation on David Lilley Most recently, David Lilley led the Commercial arm of NovaQuest from 2005 to 2008 where he and his team executed deals to prov...

Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures

...rosis scores of F0 to F3 at baseline demonstrated SVRs of 7.8% in the 9 mcg arm and 13.1% in the 15 mcg arm Patients maintaining full dose of INFERGEN/RBV therapy had SVRs of ...

Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598

...09. The current protocol design calls for 12 weeks of dosing ANA598 in naive genotype 1 patients in combination with SOC, compared to a control arm that will receive a placebo and SOC. After 12 weeks, patients are expected to continue to receive SOC alone. The primary endpoints of the study are d...

Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

...we believe pixantrone offers a valuable therapy for this unmet medical need." The most common grade 3, 4 adverse event observed on the pixantrone arm was neutropenia in 41.2% of patients versus 19.4% on the comparator arm. However, the incidence of grade 3, 4 febrile neutropenia was only 7.4% versus...

Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting

...-small cell lung cancer (NSCLC)(4). While the primary endpoint, a statistically significant improvement in PFS, was not met, the docetaxel plus AT-101 arm demonstrated a positive trend in OS, as reflected in the Kaplan-Meier curves (hazard ratio 0.82). This group also demonstrated a 33 percent increase ...

NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS

... treatment between India and Western countries. Notwithstanding the limited size of the study the survival rate at 30 months for the CRT + nimotuzumab arm was statistically superior to CRT arm, and compares favorably with historical controls performed in Western countries (Brizel DM, Albers ME, Fisher SR...

OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer

...rate of death when compared to the control arm for patients receiving 6 or less cycles of...nsistent results in favor of the OGX-011 treatment arm in this trial are a clear indication that Phase 3 ...ed below. - The OGX-011 plus docetaxel arm met the primary endpoint of the trial give...

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

...mized multiple myeloma study, 25 patients (8%) in the VELCADE for Injection arm and 42 patients (13%) in the VELCADE plus DOXIL arm experienced left ventricular ejection fraction decrease (defined as absolut...

Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients

...rt Worth. "It allows us to use the current standard of care as the control arm in future clinical studies to further advance the timely clinical developme...range, 56.9 to 60.9ml/min). The BPAR was also lowest (15.0%) in the Prograf arm when compared to the standard-dose CyA (29.0%), low-dose CyA (26.6%) or sir...

Monitoring water through a snake's eyes

...susceptible. "It's unlikely that someone will poison the water supply in Afghanistan," says Prof. Katzir, "but America is in grave danger and needs to arm itself against chemical threats to its drinking water. "With our naked eyes we can't distinguish between pure water and water that contains a small...

Smith & Nephew Endoscopy Launches the BICEPTOR(TM) Tenodesis System, the First All-Arthroscopic Procedure for Biceps Tendon Repair

... Smith & Nephew Endoscopy's BICEPTOR Tenodesis System is the first that enables surgeons to re-attach the biceps tendon to the humerus, or upper arm bone, using an all-arthroscopic technique. Other biceps tenodesis techniques require the extra step of withdrawing the damaged end of the biceps tendo...

Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial

...tandard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemother....02) with no patients in the standard chemotherapy arm achieving a confirmed complete remission. Pix...ess frequent in the pixantrone than in the control arm (1.5% vs. 13.4%). CTI will be presenting addi...

Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma

... by U.S. Food and Drug Administration under a Special Protocol Assessment (SPA), patients are permitted to "cross-over" from the best alternative care arm to receive treatment with the Delcath System at the time of disease progression. Commenting on Dr. Whitman's upcoming presentation, Richard L. Ta...

Independent Data Monitoring Committee Supports Continuation of Picoplatin Phase 3 SPEAR Registration Trial in Small Cell Lung Cancer

...by the FDA and European Medicines Agency. The study is 90 percent powered to show a 33 percent reduction in risk in overall survival for the treatment arm compared to BSC alone (hazard ratio = 0.67) (p < 0.05). Our Phase 2 study in resistant or refractory disease or patients who relapsed within 180 da...

Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research

...infections characteristic of AIDS as well as HIV itself. Ultimately this approach could be combined with traditional vaccination strategies to further arm the immune system against HIV infection. "We are very pleased that our research proposal was chosen for this prestigious award," commented Edward...

UMass Boston Opens Venture Development Center to Expand R&D Activity

...bout UMass Boston, visit www.umb.edu . About the Venture Development Center The Venture Development Center is the strategic business development arm of the Office of the Vice Provost for Research at the University of Massachusetts Boston. The VDC offers faculty, staff, and students and their partne...

Video: Turning Hope Into Reality - VA Research to Restore Veterans' Abilities

...A is launching a three-year study of an artificial arm that allows those who have lost their limb to perf... health care system. "The advanced prosthetic arm is a high-tech example of how VA researchers are c... three-year "optimization study" of the artificial arm is the first large-scale clinical trial to play an...

Richard Giltner Joins United Therapeutics Board of Directors

...s group, a position he has held since 2006. From 2003 to 2006, Mr. Giltner was the global head of foreign exchange options for the investment banking arm of Societe Generale. He has also held various other managerial positions with Societe Generale since 1991. Mr. Giltner earned a bachelor of arts deg...

Resverlogix Provides Quarterly Update

...9. As a result of the recently announced financing, completion of the third arm of the Phase 1b/2a trial has recommenced. Resverlogix is also pleased to an...ew assessment of a biomarker for Alzheimer's disease to the third and final arm of this clinical trial. "The unmet medical need of treating subjects with...

OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer

... trial will be to determine whether a greater proportion of patients in the arm treated with OGX-011 and docetaxel/prednisone experiences durable pain palliation as compared to patients in the arm treated with docetaxel/prednisone alone. It is expected that approximately ...

Former GE Healthcare Director, Per Foss Appointed CEO for HUNT Biosciences

... LEVANGER, Norway, April 23 /PRNewswire/ -- HUNT Biosciences, the commercial arm of the HUNT Study and associated biobank today announced the appointment of former GE Healthcare director Per Foss as its new CEO. The company provide...

BioMS Medical's pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board

...ts are HLA-DR2 and/or HLA-DR4 positive). Time to disease progression in patients with other HLA-DR types will be assessed separately as an exploratory arm of the same study. About BioMS Medical Corp. ------------------------- BioMS Medical is a biotechnology company engaged in the dev...

Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer

...n, defined as a PSA of 3 ng/mL or greater, men became eligible for one booster infusion of either PROVENGE or placebo in accordance with the treatment arm to which they were randomized. Patients continue to be followed for the clinical endpoints of time to distant failure, which typically would be the ap...

BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma

...ive disease which includes any type of therapy including investigational drugs. A total of 360 patients will be enrolled (240 to the OncoVEX (GM-CSF) arm and 120 to the control arm). The study design was agreed with the FDA under the Special Protocol Assessment process ("SPA"). The SPA process provide...

TrueVision Adds 3D Flat Panel Displays to its Visualization Platform for Refractive-Cataract Surgery

...tion of high quality LCD 3D 1080p panels ranging from 24 to 46 inches. One or more displays can be mounted on the wall, from the ceiling, or on a boom arm for operating rooms, exam rooms, and offices. Santa Barbara based TrueVision Systems will be presenting the flat panel products in collaboration ...

Van Andel Institute Joins the MetaMiner Oncology Partnership Program

...ieving excellence in education by probing fundamental issues of education and the learning process. Van Andel Research Institute (VARI), the research arm of VAI, is dedicated to probing the genetic, cellular and molecular origins of cancer, Parkinson and other diseases and working to translate those fin...

NeuroSky to Launch Brainwave-Based Technology for Stereo Headsets for Personal Computers

...in the mainstream of personal computer users. The MindSet headset resembles a pair of headphones with one distinct difference--an electrode-laden arm that is in contact with the user's forehead. The electrode reads the electrical potentials found on the skin's surface and induced by the neuron acti...

Batman Teams with Senator Katherine Laforge to Help Free America from OPEC

...about freeing us from OPEC’s clutches reads, “The oil industry has become American’s shadow government complete with free use of our arm forces to protect its products and profits. Our service men and women die to protect their profits, and billions in tax dollars are used to support th...